Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3
The US Food and Drug Administration (FDA) has approved suzetrigine 50 mg tablets, a first-in-class nonopioid analgesic for treatment of adults with moderate-to-severe acute pain.
As the use of glucagon-like peptide 1 receptor agonists continues to exponentially expand obesity treatment, concerns have arisen regarding their impact on nutrition in people who take them